0RQJ Stock Chart & Stats
kr21.15
kr0.05(0.69%)
At close: 4:00 PM EST
kr21.15
kr0.05(0.69%)
Day’s Range― - ―
52-Week Rangekr11.12 - kr28.15
Previous CloseN/A
Volume372.00
Average Volume (3M)4.89K
Market Cap
kr1.64B
Enterprise Valuekr1.32K
Total Cash (Recent Filing)kr486.31M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)8.7
Beta0.87
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.34
Shares Outstanding138,030,140
10 Day Avg. Volume5,513
30 Day Avg. Volume4,893
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr11.00M
Bulls Say, Bears Say
Bulls Say
Sharp Profitability ImprovementThe turnaround demonstrates substantial recent earnings power and improved operating economics. If supported by recurring collaboration income or milestones, this profitability could provide greater financial flexibility for advancing the pipeline.
Debt-Free Balance SheetA debt-free structure reduces interest burden and refinancing risk, giving Saniona more flexibility to fund clinical programs and negotiate partnerships. Strong current equity also provides a buffer against the volatility typical of development-stage biotechnology.
Positive Free Cash FlowPositive operating and free cash flow across the latest reported periods can reduce reliance on equity financing and support continued research investment. Sustained cash generation would strengthen Saniona’s ability to progress candidates between partnering milestones.
Bears Say
Extreme Revenue VolatilityThe sharp reversal indicates limited revenue visibility and likely dependence on irregular licensing or milestone income. Such volatility makes current profitability difficult to extrapolate and can complicate planning, pipeline funding, and partner negotiations.
Inconsistent Cash ConversionCash generation is positive but does not consistently match reported earnings, while year-to-year changes are choppy. This weakens confidence in the durability of accounting profits and may increase future dependence on milestone receipts or capital raises.
Recent Capital Structure InstabilityThe recent balance-sheet recovery is encouraging, but the prior leverage and negative-equity period shows that financial stability has not been consistent. A setback in development or partnering could therefore renew pressure on capital and shareholder funding.
Saniona AB News
0RQJ FAQ
What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest share price was kr11.12 and its highest was kr28.15 in the past 12 months.
What is Saniona AB’s market cap?
Saniona AB’s market cap is kr1.64B.
When is Saniona AB’s upcoming earnings report date?
Saniona AB’s upcoming earnings report date is Nov 26, 2026 which is in 89 days.
How were Saniona AB’s earnings last quarter?
Saniona AB released its earnings results on Aug 27, 2026. The company reported -kr0.422 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Saniona AB overvalued?
According to Wall Street analysts Saniona AB’s price is currently Overvalued.
Does Saniona AB pay dividends?
Saniona AB does not currently pay dividends.
What is Saniona AB’s EPS estimate?
Saniona AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Saniona AB have?
Saniona AB has 138,030,140 shares outstanding.
What happened to Saniona AB’s price movement after its last earnings report?
Saniona AB reported an EPS of -kr0.422 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.932%.
Which hedge fund is a major shareholder of Saniona AB?
Currently, no hedge funds are holding shares in GB:0RQJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Saniona AB
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
Technical Analysis
Hansa Biopharma AB
―
Medivir AB
―
Camurus AB
―
AlzeCure Pharma AB
―
BioArctic AB Class B
―